Subsidiary company exposed good “flash collapse stock” Jimin pharmaceutical saved?

Jimin Pharmaceutical (603222) has broken the hearts of too many shareholders for eight consecutive trading days. Recently, the company announced that the subsidiary signed a major contract of 540 million yuan, which was interpreted as a major positive by some shareholders. It is expected that Jimin pharmaceutical will end the continuous “one word” drop limit situation as soon as possible on December 28 or in the near future, but whether the wishes of investors can come true is still unknown. < / P > < p > Jimin pharmaceutical once suddenly broke down its limit in the afternoon of December 16, and then dropped its limit for seven consecutive times. As of December 25, 2020, Jimin pharmaceutical’s share price closed at 17.99 yuan / share. From December 16 to 25, Jimin pharmaceutical’s stock price fell as high as 56.95% in eight trading days, while the market rose by 0.87% in the same period. < / P > < p > according to the announcement of Jimin pharmaceutical on the evening of December 25, Jumin Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently cooperated with retractable technologies, Inc. The second amendment to the production agreement was signed, involving 900 million safety injection needles and safety syringes, with a total amount of about 540 million yuan, accounting for about 70.04% of the audited business revenue of Jimin pharmaceutical in 2019. < / P > < p > regarding the impact of signing this Agreement on the company, Jimin pharmaceutical said that the performance period of this contract is from January 2021 to June 2023, which will not affect the performance of the company this year. < / P > < p > in fact, Jimin pharmaceutical’s flash collapse is the second time this year. As early as June 11, the stock price of Jimin pharmaceutical reached an all-time high, at 57.45 yuan per share. On the same day, investors bought 1.55 billion yuan. Then Jimin pharmaceutical fell its trading limit for three consecutive trading days on June 12, 15 and 16, and the sudden collapse of Jimin pharmaceutical killed the investors who were chasing the high price. On June 17, Jimin pharmaceutical announced that some people in the market used wechat group, QQ group and live broadcast room to recommend buying Jimin pharmaceutical shares. According to the self inspection of the company, the relevant personnel of the company did not plan and participate in the event. < / P > < p > now, in the face of Jimin pharmaceutical’s collapse again, shareholders want to cry without tears, hoping to end the continuous “one” drop limit situation as soon as possible. But even if there is a positive blessing, Jimin pharmaceutical when to lift the “one” word limit is still unknown. According to the market, there were only 4524 transactions on December 25, with a turnover of 8.14 million yuan and a turnover rate of 0.41%. As of the close of December 25, Jimin pharmaceutical still had about 460000 orders waiting to be sold on the daily limit, with a corresponding market value of about 828 million yuan. < / P > < p > however, the enthusiasm of fund bottom hunting is not enthusiastic. After hours on December 25, according to the public information of the exchange, the top five companies with the largest purchase amount of Jimin pharmaceutical’s shares were about 3.0421 million yuan. Among them, the purchase amount of Zhongbei Road Securities Business Department of CITIC Securities Co., Ltd., which has the largest purchase amount, is about 1.1963 million yuan, while the purchase amount of the remaining four seats is less than 1 million yuan. < / P > < p > for the recent stock price fluctuations, Jimin pharmaceutical announced in the evening of December 25 that through the company’s self-examination, no other matters have occurred, the company’s production and operation are normal, the internal and external business environment has not changed significantly, and there are no important matters that should be disclosed but not disclosed. The company’s non-public offering has been approved and approved by the CSRC, and is being carried out in an orderly manner. < / P > < p > in view of the recent stock price collapse of Jimin pharmaceutical and other related problems, Beijing Business Daily reporter repeatedly called the office of the Secretary of Jimin pharmaceutical, but no one answered. < / P > < p > Disclaimer: the purpose of this article reprinted by CNFC is to convey more information, and it does not represent the opinions and positions of CNFC. The content of this article is for reference only, and does not constitute an investment proposal. Investors operate on this basis at their own risk. < p > < p > Chinanet is a state key news website under the leadership of the Information Office of the State Council and the management of China foreign language publishing and Distribution Bureau. Through 11 versions in 10 languages, the website publishes information 24 hours a day. It is an important window for China to carry out international communication and information exchange.